Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -5.50% |
management commentary, guidance changes, and full analysis available with Pro.
| -5.50% |
Tone: Defensive
Management expressed cautiousness regarding current performance. They acknowledged the difficulties faced in achieving expected results.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized a focus on long-term strategies despite short-term setbacks.
Nektar Therapeutics reported a larger-than-expected loss per share, but the stock rose by 2.81% following the announcement. This increase could indicate investor optimism about the company's long-term potential despite the current financial challenges. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019